News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celltech Group PLC (CLL) Announces Completion Of Oxford GlycoSciences PLC (LS:OGS) Integration Process


10/19/2005 5:10:49 PM

Celltech Group plc (LSE:CCH) (NYSE:CLL) announced today that it has completed its integration of Oxford GlycoSciences (OGS), which was acquired in May 2003. This acquisition has provided Celltech with substantial assets, including six novel oncology research programmes supported by around 40 high quality scientists, a royalty stream from the marketed product Zavesca(R), and a Phase I development programme, CDP 923, for the treatment of certain inherited storage disorders. The acquisition has met Celltech's goal of being both cash and earnings neutral.

Read at Prime Zone

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES